← Back to Clinical Trials
Recruiting NCT06457139

NCT06457139 Preventing T2DM After GDM With Immediate Postpartum Screening

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06457139
Status Recruiting
Phase
Sponsor University of Massachusetts, Worcester
Condition Gestational Diabetes
Study Type INTERVENTIONAL
Enrollment 116 participants
Start Date 2025-06-01
Primary Completion 2028-06-01

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Glucose tolerance test (2 hour)Active Comparator

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 116 participants in total. It began in 2025-06-01 with a primary completion date of 2028-06-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The overall goal of this proposal is to create and test an implementation protocol for in-hospital immediate postpartum diabetes screening for postpartum patients with pregnancies affected by GDM.

Eligibility Criteria

Inclusion Criteria: * pregnancy complicated by GDM as diagnosed with traditional two step testing in the third trimester according to Carpenter-Coustan Criteria * receiving prenatal care at UMASS Memorial and plans to deliver at UMASS Memorial * able and willing to provide informed consent * ability to complete immediate in hospital postpartum glucose testing * have evidence of impaired glucose metabolism defined as fasting glucose value of ≥126 mg/dL or 2-hour glucose value of ≥200 mg/dL Exclusion Criteria: * known diagnosis of pre-existing pre-gestational diabetes in pregnancy * inability to complete oral glucose tolerance test (e.g. gastric bypass surgery history, gastric dumping syndrome history, vomiting of oral glucose tolerance test) in pregnancy or immediately postpartum * systemic steroid use

Contact & Investigator

Central Contact

Gianna Wilkie, MD

✉ Gianna.Wilkie@umassmemorial.org

📞 508-3444982

Principal Investigator

Gianna Wilkie, MD

PRINCIPAL INVESTIGATOR

UMASS Memorial Healthcare

Frequently Asked Questions

Who can join the NCT06457139 clinical trial?

This trial is open to female participants only, aged 18 Years or older, studying Gestational Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06457139 currently recruiting?

Yes, NCT06457139 is actively recruiting participants. Contact the research team at Gianna.Wilkie@umassmemorial.org for enrollment information.

Where is the NCT06457139 trial being conducted?

This trial is being conducted at Worcester, United States.

Who is sponsoring the NCT06457139 clinical trial?

NCT06457139 is sponsored by University of Massachusetts, Worcester. The principal investigator is Gianna Wilkie, MD at UMASS Memorial Healthcare. The trial plans to enroll 116 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology